{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:12:28Z","timestamp":1759961548852,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.revmed.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T21:29:08Z","timestamp":1440797348000},"page":"813-817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quelle place pour les anticoagulants oraux directs en pratique hospitali\u00e8re quotidienne\u00a0?"],"prefix":"10.1016","volume":"36","author":[{"given":"M.","family":"Khetta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tharasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Le besnerais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Cailleux-Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3719-4139","authenticated-orcid":false,"given":"N.","family":"Girszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sauv\u00eatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2015.06.006_bib0190","unstructured":"ANSM. Rapport\u00a0\u2013\u00a0les anticoagulants en France en 2012. http:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Les-nouveaux-anticoagulants-oraux-Pradaxa-Xarelto-Eliquis-Des-medicaments-sous-surveillance-renforcee-Point-d-information-Actualise-le-09-10-2013. Acc\u00e8s au site le 9\/10\/2013."},{"key":"10.1016\/j.revmed.2015.06.006_bib0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","article-title":"Polypharmacy in elderly patients","volume":"5","author":"Hajjar","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.revmed.2015.06.006_bib0200","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0205","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bmj.325.7372.1073","article-title":"Oral anticoagulation and risk of death: a medical record linkage study","volume":"325","author":"Od\u00e9n","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2015.06.006_bib0210","unstructured":"DRESS. Enqu\u00eate nationale sur les \u00e9v\u00e9nements ind\u00e9sirables graves associ\u00e9s aux soins \u2013 description des r\u00e9sultats 2009. http:\/\/www.drees.sante.gouv.fr\/enquete-nationale-sur-les-evenements-indesirables-graves-associes-aux-soins-description-des-resultats-2009,9499.html. Acc\u00e8s au site le 19\/09\/2011."},{"key":"10.1016\/j.revmed.2015.06.006_bib0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","article-title":"Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention","volume":"95","author":"Landefeld","year":"1993","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.revmed.2015.06.006_bib0220","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.revmed.2009.02.004","article-title":"Exp\u00e9rience d\u2019un centre de suivi et de conseil des traitements anticoagulants oraux en m\u00e9decine de ville\u00a0: r\u00e9sultats \u00e0 cinq ans","volume":"30","author":"Benhamou","year":"2009","journal-title":"Rev Med Interne"},{"issue":"9","key":"10.1016\/j.revmed.2015.06.006_bib0225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.revmed.2013.02.001","article-title":"Les cliniques d\u2019anticoagulants sont-elles efficaces en France\u00a0? \u00c9valuation des performances de six cliniques dans la gestion des traitements par antivitamines K","volume":"34","author":"Cambus","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2015.06.006_bib0230","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(98)04147-6","article-title":"Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation","volume":"352","author":"Poller","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2015.06.006_bib0235","first-page":"CD008600","article-title":"Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation","volume":"6","author":"Clarkesmith","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2015.06.006_bib0240","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0245","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0250","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0255","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0260","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2015.06.006_bib0265","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0270","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0275","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0280","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0285","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2015.06.006_bib0290","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1177\/1060028013504741","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?","volume":"47","author":"Hellwig","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.revmed.2015.06.006_bib0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","article-title":"New oral anticoagulants: comparative pharmacology with vitamin K antagonists","volume":"52","author":"Scaglione","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.revmed.2015.06.006_bib0300","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.revmed.2015.06.006_bib0305","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2015.06.006_bib0310","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.ijcard.2012.12.076","article-title":"Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study","volume":"168","author":"Lip","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2015.06.006_bib0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2015.06.006_bib0320","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0325","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0330","unstructured":"CNAM. Nouveaux anti-coagulants oraux\u00a0: une \u00e9tude de l\u2019Assurance Maladie souligne la dynamique forte de ces nouveaux m\u00e9dicaments et la n\u00e9cessit\u00e9 d\u2019une vigilance accrue dans leur utilisation. http:\/\/ansm.sante.fr\/content\/download\/56115\/722405\/version\/1\/file\/DP-Etude-Cnam-NACO-2013.pdf. Acc\u00e8s au site le 01\/10\/2014. Publi\u00e9 en ligne le 27\/11\/2013."},{"key":"10.1016\/j.revmed.2015.06.006_bib0335","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1523-1755.2004.00412.x","article-title":"Estimating the prevalence of renal insufficiency in seniors requiring long-term care","volume":"65","author":"Garg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2015.06.006_bib0340","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2015.06.006_bib0345","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2015.06.006_bib0350","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.seminhematol.2014.02.002","article-title":"Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding","volume":"51","author":"Palareti","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1016\/j.revmed.2015.06.006_bib0355","doi-asserted-by":"crossref","unstructured":"HAS. Prise en charge des surdosages en antivitamines K, des situations \u00e0 risque h\u00e9morragique et des accidents h\u00e9morragiques chez les patients trait\u00e9s par antivitamines K en ville et en milieu hospitalier (avril 2008). http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2008-09\/surdosage_en_avk_situations_a_risque_et_accidents_hemorragiques_-_synthese_des_recommandations_v2.pdf. Acc\u00e8s au site le 01\/10\/2014.","DOI":"10.1016\/S1261-694X(09)74644-9"},{"key":"10.1016\/j.revmed.2015.06.006_bib0360","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.annfar.2013.04.016","article-title":"Prise en charge des complications h\u00e9morragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d\u2019int\u00e9r\u00eat en H\u00e9mostase P\u00e9riop\u00e9ratoire (GIHP)\u00a0\u2013\u00a0mars 2013","volume":"32","author":"Pernod","year":"2013","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.revmed.2015.06.006_bib0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1525-1497.2001.016002077.x","article-title":"Reducing medication regimen complexity: a controlled trial","volume":"16","author":"Muir","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.revmed.2015.06.006_bib0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-014-2993-8","article-title":"Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism","volume":"30","author":"Leiss","year":"2015","journal-title":"J Gen Intern Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866315005512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866315005512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:35:35Z","timestamp":1759336535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866315005512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0248866315005512"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2015.06.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quelle place pour les anticoagulants oraux directs en pratique hospitali\u00e8re quotidienne\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2015.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}